Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of darolutamide plus ADT versus placebo plus ADT in metastatic hormone-sensitive prostate cancer
CTR20211820Phase 3Completed
- Sponsor
- Bayer
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of darolutamide in prostate cancer (PCa), sponsored by Bayer. Started Oct 2021; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20211820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211820.